Total Payments
$4,176
2024 Payments
$313.00
Companies
12
Transactions
22
Medicare Patients
1,278
Medicare Billing
$249,074
Payment Breakdown by Category
Food & Beverage$1,532 (36.7%)
Other$1,500 (35.9%)
Consulting$1,100 (26.3%)
Education$44.64 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,532 | 17 | 36.7% |
| Honoraria | $1,500 | 1 | 35.9% |
| Consulting Fee | $1,100 | 1 | 26.3% |
| Education | $44.64 | 3 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| G1 Therapeutics, Inc. | $1,500 | 1 | $0 (2022) |
| Adaptive Biotechnologies Corporation | $1,259 | 3 | $0 (2022) |
| Celgene Corporation | $364.46 | 3 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $252.02 | 4 | $0 (2023) |
| ABBVIE INC. | $167.94 | 3 | $0 (2024) |
| GENZYME CORPORATION | $159.91 | 2 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $125.00 | 1 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $119.38 | 1 | $0 (2019) |
| Tempus AI, Inc | $95.83 | 1 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $71.77 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $313.00 | 5 | ABBVIE INC. ($167.94) |
| 2023 | $210.02 | 3 | E.R. Squibb & Sons, L.L.C. ($138.25) |
| 2022 | $2,877 | 5 | G1 Therapeutics, Inc. ($1,500) |
| 2021 | $53.38 | 2 | Adaptive Biotechnologies Corporation ($41.46) |
| 2020 | $141.14 | 2 | Janssen Pharmaceuticals, Inc ($125.00) |
| 2019 | $337.66 | 3 | Celgene Corporation ($120.65) |
| 2017 | $243.81 | 2 | Celgene Corporation ($243.81) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/04/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $49.23 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 08/20/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $95.83 | General |
| 05/01/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: ONCOLOGY | ||||||
| 02/24/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $65.66 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $74.78 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2023 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $71.77 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/30/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $16.58 | General |
| Category: Oncology | ||||||
| 02/09/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $121.67 | General |
| Category: Oncology | ||||||
| 09/28/2022 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | In-kind items and services | $117.23 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 08/31/2022 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $142.23 | General |
| Category: Hematology | ||||||
| 06/14/2022 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Hematology | ||||||
| 05/26/2022 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 04/27/2022 | G1 Therapeutics, Inc. | COSELA (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2021 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | In-kind items and services | $41.46 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 07/13/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $16.14 | General |
| Category: Oncology | ||||||
| 01/15/2020 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/27/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $97.63 | General |
| Category: Oncology | ||||||
| 04/23/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $119.38 | General |
| Category: ONCOLOGY | ||||||
| 04/01/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $120.65 | General |
| Category: Hematology / Oncology | ||||||
| 07/26/2017 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $128.81 | General |
| Category: Hematology / Oncology | ||||||
| 03/02/2017 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $115.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 360 | 752 | $245,909 | $72,530 |
| 2022 | 9 | 323 | 753 | $207,042 | $62,075 |
| 2021 | 8 | 326 | 690 | $203,579 | $63,386 |
| 2020 | 7 | 269 | 623 | $173,600 | $51,082 |
Total Patients
1,278
Total Services
2,818
Medicare Billing
$249,074
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 73 | 339 | $127,125 | $37,004 | 29.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 96 | 154 | $42,966 | $11,015 | 25.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 100 | $18,300 | $9,162 | 50.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 44 | 47 | $24,816 | $6,195 | 25.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 31 | 31 | $16,647 | $3,987 | 23.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 38 | $4,864 | $2,314 | 47.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 29 | 30 | $5,640 | $1,521 | 27.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $5,551 | $1,332 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 82 | 325 | $86,125 | $23,762 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 43 | 153 | $54,621 | $16,723 | 30.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 42 | 87 | $15,138 | $6,977 | 46.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 30 | 30 | $12,180 | $3,137 | 25.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 50 | 63 | $11,277 | $2,690 | 23.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 44 | $5,324 | $2,409 | 45.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $7,530 | $2,187 | 29.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 21 | $7,182 | $2,131 | 29.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $7,665 | $2,059 | 26.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 41 | 195 | $69,615 | $21,783 | 31.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 81 | 206 | $54,590 | $15,376 | 28.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 45 | 100 | $17,400 | $8,114 | 46.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 43 | 43 | $21,586 | $6,762 | 31.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 32 | 32 | $16,352 | $4,214 | 25.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 21 | 47 | $5,687 | $2,681 | 47.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 28 | 28 | $11,368 | $2,459 | 21.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 35 | 39 | $6,981 | $1,998 | 28.6% |
About Dr. Arun Sendilnathan, M.D
Dr. Arun Sendilnathan, M.D is a Hematology & Oncology healthcare provider based in Hamilton, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2011. The National Provider Identifier (NPI) number assigned to this provider is 1013298223.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arun Sendilnathan, M.D has received a total of $4,176 in payments from pharmaceutical and medical device companies, with $313.00 received in 2024. These payments were reported across 22 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($1,532).
As a Medicare-enrolled provider, Sendilnathan has provided services to 1,278 Medicare beneficiaries, totaling 2,818 services with total Medicare billing of $249,074. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Hamilton, OH
- Active Since 08/31/2011
- Last Updated 10/12/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1013298223
Products in Payments
- COSELA (Drug) $1,500
- clonoSEQ (Device) $1,259
- OPDIVO (Biological) $252.02
- Revlimid (Drug) $249.46
- CABLIVI (Biological) $142.23
- EPKINLY (Drug) $140.44
- INVOKANA (Drug) $125.00
- KEYTRUDA (Biological) $119.38
- ZEPZELCA (Drug) $71.77
- PROVENGE (Drug) $49.23
- IMBRUVICA (Drug) $27.50
- ENJAYMO (Biological) $17.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.